Preliminary study on alternative half body irradiation in the treatment of hematological malignancies.
- Author:
Jia-Lin WEI
1
;
Mei WANG
;
De-Hui ZOU
;
Dong-Lin YANG
;
Rui LI
;
Jun NING
;
Si-Zhou FENG
;
Ming-Zhe HAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Female; Hematologic Neoplasms; drug therapy; radiotherapy; Hemibody Irradiation; adverse effects; methods; Humans; Male; Middle Aged; Treatment Outcome
- From: Chinese Journal of Hematology 2004;25(6):355-358
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the curative effect of alternative half body irradiation (AHBI) in the treatment of hematological malignancies.
METHODSSeventeen patients with hematological malignancies in complete remission received a high-dose chemotherapy, followed by a two-step AHBI on day 14 (12 approximately 22), upper (UHBI) and lower half body irradiation (LHBI) were sequentially given with each a single dose of 6 approximately 9 Gy at an interval of 23 (7 approximately 34) days. Fourteen received autologous hematopoietic stem cell transplantation (AHSCT) during the same period were chosen as control.
RESULTSHematopoiesis recovery was observed in all the AHBI patients. The 3-year disease free survival (DFS) rate and the AHBI-related mortality were (52.38 +/- 13.47)% and 0, respectively. The longest survival time was 1446 days with a median follow-up period of 927 (428 approximately 1446) days. The 3-year DFS for the 11 acute lymphocytic leukemia (ALL) patients was (47.73 +/- 17.55)%. By contrast, the 3-year DFS and the AHSCT-related mortality for the 14 ALL patients in the control AHSCT group were (53.88 +/- 14.08)% and 14%, respectively. There was no significant difference in 3-year DFS between AHBI and AHSCT ALL patients.
CONCLUSIONSAHBI provides a feasible approach for hematological malignancy patients.
